BCDA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.300

Open

1.300

VWAP

1.00

Vol

76.00K

Mkt Cap

13.00M

Low

1.230

Amount

96.00K

EV/EBITDA(TTM)

--

Total Shares

11.00M

EV

9.00M

EV/OCF(TTM)

--

P/S(TTM)

--

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

Show More

Events Timeline

(ET)

2025-12-16

08:10:00

BioCardia Completes Third Clinical Consultation with Japan's PMDA

2025-12-03 (ET)

2025-12-03

08:20:00

BioCardia Appoints Marvin Slosman to Board of Directors

2025-11-24 (ET)

2025-11-24

08:35:51

BioCardia Names Farhan Shahab as Vice President of Quality

2025-11-10 (ET)

2025-11-10

08:40:42

BioCardia Enrolls First Patient at Henry Ford Health for Phase 3 CardiAMP Trial

2025-10-30 (ET)

2025-10-30

08:22:19

BioCardia Reports Enrollment of Patient in CardiAMP Trial at Wisconsin School

2025-10-02 (ET)

2025-10-02

08:08:32

BioCardia Meets Nasdaq Listing Standards Again

2025-09-22 (ET)

2025-09-22

08:02:20

BioCardia Reveals Initial Discussions with Japan's PDMA Regarding CardiAMP Findings

2025-09-18 (ET)

2025-09-18

09:22:55

BioCardia sets public offering price at $1.25 for 4.8 million shares

2025-09-18

07:02:22

BioCardia Reveals Results of CardiAMP Cell Therapy

2025-09-16 (ET)

2025-09-16

09:07:10

BioCardia Seeks Approval to Offer 2.8 Million Shares of Common Stock and Warrants

News

an image of NASDAQ.COM

01-22NASDAQ.COM

IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%

an image of Newsfilter

2025-12-16Newsfilter

BioCardia Completes Third Clinical Consultation with Japan's PMDA for CardiAMP Therapy

an image of Newsfilter

2025-12-03Newsfilter

BioCardia Elects Marvin Slosman to Board of Directors

an image of Yahoo Finance

2025-11-24Yahoo Finance

BioCardia Enhances Leadership Team by Appointing Farhan Shahab as Vice President of Quality

an image of NASDAQ.COM

2025-11-13NASDAQ.COM

BioCardia, Inc. Reports Smaller Q3 Loss, Surpassing Expectations

an image of Newsfilter

2025-11-06Newsfilter

BioCardia to Hold Conference Call on November 12, 2025, for Q3 2025 Corporate Update and Financial Results

2 Analyst Rating

Wall Street analysts forecast BCDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCDA is 15.50 USD with a low forecast of 6.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

6.00

Averages

15.50

High

25.00

Current: 0.000

Low

6.00

Averages

15.50

High

25.00

an image of No data

No data

Valuation Metrics

The current forward P/E ratio for BioCardia Inc (BCDA.O) is -1.48, compared to its 5-year average forward P/E of -2.96. For a more detailed relative valuation and DCF analysis to assess BioCardia Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-2.96

Current PE

-1.48

Overvalued PE

-0.47

Undervalued PE

-5.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-1.21

Current EV/EBITDA

-0.93

Overvalued EV/EBITDA

-0.15

Undervalued EV/EBITDA

-2.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

117.51

Current PS

0.00

Overvalued PS

308.77

Undervalued PS

-73.75

Financials

AI Analysis

Annual

Quarterly

Whales Holding BCDA

Trading Trends

People Also Watch

Frequently Asked Questions

What is BioCardia Inc (BCDA) stock price today?

The current price of BCDA is 1.26 USD — it has decreased -3.08 % in the last trading day.

What is BioCardia Inc (BCDA)'s business?

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

What is the price predicton of BCDA Stock?

Wall Street analysts forecast BCDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCDA is15.50 USD with a low forecast of 6.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is BioCardia Inc (BCDA)'s revenue for the last quarter?

BioCardia Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is BioCardia Inc (BCDA)'s earnings per share (EPS) for the last quarter?

BioCardia Inc. EPS for the last quarter amounts to -0.24 USD, decreased -60.66 % YoY.

How many employees does BioCardia Inc (BCDA). have?

BioCardia Inc (BCDA) has 17 emplpoyees as of January 30 2026.

What is BioCardia Inc (BCDA) market cap?

Today BCDA has the market capitalization of 13.00M USD.